Castle Biosciences, Inc. (CSTL) Income Statement
CSTL 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsCSTL revenue and net income
Where CSTL's revenue goes
2025Each bar shows an amount and its share of revenue. CSTL kept −7.0% of revenue as net income.
CSTL profit margins
CSTL growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +3.7% | +35.9% | +40.6% | — |
| Gross profit | +0.5% | +37.5% | +38.8% | — |
| Operating income | −593.8% | — | — | — |
| Net income | −232.4% | — | — | — |
| EPS (diluted) | −237.1% | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CSTL quarterly EPS vs estimates
Castle Biosciences beat the analyst EPS estimate in 7 of the last 8 quarters. Next report: November 5, 2026 (estimate $-0.38).
CSTL income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $344.2M | $332.1M | $219.8M | $137.0M | $94.1M | $62.6M | $51.9M | $22.8M | $13.8M |
| Cost of revenue | $71.0M | $60.2M | $45.0M | $32.0M | $15.8M | $9.7M | $7.3M | $5.3M | $4.9M |
| Gross profit | $273.2M | $271.9M | $174.8M | $105.0M | $78.3M | $53.0M | $44.6M | $17.5M | $8.8M |
| Research & development | $51.9M | $52.0M | $53.6M | $44.9M | $29.6M | $13.3M | $7.4M | $4.9M | $4.5M |
| Sales, general & admin | $229.3M | $200.0M | $180.2M | $56.4M | $86.7M | $48.1M | $29.8M | $16.5M | $15.3M |
| Total operating expenses | $316.0M | $263.2M | $242.8M | $177.9M | $118.3M | $59.5M | $37.2M | $21.3M | $19.7M |
| Operating income | −$42.8M | $8.7M | −$68.0M | −$72.9M | −$40.1M | −$6.5M | $7.3M | −$3.8M | −$10.9M |
| Interest income | $11.8M | $12.9M | $9.8M | $4.0M | $68,000 | $373,000 | $312,000 | $23,514 | $26,184 |
| Interest expense | $86,000 | $577,000 | $11,000 | $17,000 | $1,000 | $2.6M | $4.6M | $2.3M | $1.6M |
| Income before taxes | −$29.5M | $21.6M | −$57.4M | −$68.9M | −$40.0M | −$10.2M | $5.3M | −$6.4M | −$12.4M |
| Income taxes | −$5.4M | $3.3M | $101,000 | −$1.8M | −$8.7M | $84,000 | $72,000 | $8,606 | $9,731 |
| Net income | −$24.2M | $18.2M | −$57.5M | −$67.1M | −$31.3M | −$10.3M | $5.3M | −$6.4M | −$12.4M |
| EBITDA | $11.3M | $38.1M | −$45.0M | −$58.3M | −$36.6M | −$7.1M | $10.3M | −$3.8M | −$10.4M |
| EPS (diluted) | −$0.85 | $0.62 | −$2.16 | −$2.58 | −$1.24 | −$0.45 | −$2.14 | −$0.60 | — |
| Gross margin | 79.4% | 81.9% | 79.5% | 76.6% | 83.2% | 84.5% | 85.9% | 76.8% | 64.2% |
| Operating margin | −12.4% | 2.6% | −30.9% | −53.2% | −42.6% | −10.4% | 14.1% | −16.8% | −79.2% |
| Net margin | −7.0% | 5.5% | −26.1% | −49.0% | −33.3% | −16.4% | 10.2% | −27.9% | −89.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $103.5M | $83.7M | $87.0M | $83.0M | $86.2M | $88.0M | $86.3M | $85.8M | $87.0M | $73.0M | $66.1M | $61.5M |
| Cost of revenue | $23.7M | $20.5M | $18.3M | $18.7M | $17.6M | $16.4M | $16.2M | $15.6M | $14.5M | $13.9M | $12.4M | $11.3M |
| Gross profit | $79.8M | $63.1M | $68.7M | $64.3M | $68.6M | $71.6M | $70.1M | $70.2M | $72.5M | $59.1M | $53.7M | $50.2M |
| Research & development | $14.5M | $14.4M | $13.5M | $13.0M | $12.8M | $12.6M | $11.7M | $12.3M | $14.1M | $13.8M | $13.0M | $12.9M |
| Sales, general & admin | $66.1M | $64.9M | $56.7M | $55.9M | $58.1M | $58.6M | $50.0M | $50.5M | $51.1M | $48.5M | $44.1M | $44.6M |
| Total operating expenses | $82.9M | $81.6M | $72.5M | $71.1M | $72.8M | $99.5M | $66.1M | $65.1M | $67.5M | $64.6M | $59.4M | $59.8M |
| Operating income | −$3.1M | −$18.4M | −$3.8M | −$6.8M | −$4.3M | −$27.9M | $4.0M | $5.1M | $5.0M | −$5.5M | −$5.7M | −$9.6M |
| Interest income | $2.4M | $2.5M | $2.9M | $2.8M | $2.9M | $3.1M | $3.4M | $3.4M | $3.1M | $3.0M | $3.1M | $2.8M |
| Interest expense | $193,000 | $134,000 | $24,000 | $24,000 | $21,000 | $17,000 | $92,000 | $201,000 | $270,000 | $14,000 | $2,000 | $2,000 |
| Income before taxes | −$1.7M | −$14.4M | −$2.7M | −$386,000 | −$143,000 | −$26.3M | $7.9M | $8.3M | $7.9M | −$2.5M | −$2.5M | −$6.9M |
| Income taxes | $370,000 | $109,000 | −$382,000 | $115,000 | −$4.7M | −$423,000 | −$1.7M | $6.0M | −$1.0M | $45,000 | $39,000 | $32,000 |
| Net income | −$2.1M | −$14.5M | −$2.3M | −$501,000 | $4.5M | −$25.8M | $9.6M | $2.3M | $8.9M | −$2.5M | −$2.6M | −$6.9M |
| EBITDA | $2.6M | −$10.3M | $1.1M | $3.5M | $3.3M | $3.5M | $13.7M | $12.0M | $11.5M | $865,000 | $685,000 | −$3.7M |
| EPS (diluted) | −$0.07 | −$0.49 | −$0.08 | −$0.02 | $0.15 | −$0.90 | $0.32 | $0.08 | $0.31 | −$0.09 | −$0.10 | −$0.26 |
| Gross margin | 77.1% | 75.5% | 79.0% | 77.5% | 79.5% | 81.4% | 81.3% | 81.8% | 83.3% | 81.0% | 81.2% | 81.6% |
| Operating margin | −3.0% | −22.0% | −4.4% | −8.2% | −4.9% | −31.7% | 4.7% | 5.9% | 5.8% | −7.5% | −8.6% | −15.7% |
| Net margin | −2.0% | −17.4% | −2.7% | −0.6% | 5.2% | −29.4% | 11.1% | 2.6% | 10.3% | −3.5% | −3.9% | −11.2% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CSTL's financial statements (latest annual report filed February 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CSTL financial results
In fiscal year 2025 (ended December 31, 2025), Castle Biosciences reported revenue of $344.2 million, up 3.7% from the year before. It had a net loss of $24.2 million, a net profit margin of −7.0%. Diluted earnings per share came to −$0.85. Over five years revenue grew at an average rate of 40.6% a year.
See the CSTL stock overview for the latest quote and news, or the CSTL chart for price history and technical indicators.
CSTL income statement FAQ
What is Castle Biosciences's annual revenue?
Castle Biosciences reported total revenue of $344.2 million for fiscal year 2025, which ended on December 31, 2025. That was up 3.7% from $332.1 million the previous year.
Is Castle Biosciences profitable?
No. Castle Biosciences reported a net loss of $24.2 million in fiscal 2025, a net profit margin of −7.0%; its operating margin was −12.4%.
What is Castle Biosciences's gross margin?
Castle Biosciences's gross margin was 79.4% in fiscal 2025: for every $100 of revenue, Castle Biosciences kept $79 after the direct cost of its products and services.
How much does Castle Biosciences spend on research and development?
Castle Biosciences spent $51.9 million on research and development in fiscal 2025, 15.1% of revenue.
How fast is Castle Biosciences growing?
Revenue grew 40.6% a year on average over the last five fiscal years, from $62.6 million to $344.2 million.
What are Castle Biosciences's earnings per share?
Castle Biosciences earned $-0.85 per diluted share in fiscal 2025, compared with $0.62 a year earlier.
When will Castle Biosciences report its next earnings?
Castle Biosciences is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes.
When does Castle Biosciences's fiscal year end?
Castle Biosciences's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 26, 2026.